Quick Answer
Solid Biosciences Inc. reported Research And Development Expense of $140.33 million for the year ending 2025.
- Solid Biosciences Inc. showed an increase of +45.5% in Research And Development Expense from 2024 to 2025.
- This data is from Solid Biosciences Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $8.73 million | Q2 2017: $8.61 million | Q3 2017: $10.62 million | Q1 2018: $11.93 million | Q2 2018: $13.59 million | Q3 2018: $14.68 million | Q1 2019: $23.27 million | Q2 2019: $21.61 million | Q3 2019: $22.79 million | Q1 2020: $19.67 million | Q2 2020: $13.45 million | Q3 2020: $16.05 million | Q1 2021: $14.21 million | Q2 2021: $15.51 million | Q3 2021: $14.43 million | Q1 2022: $19.95 million | Q2 2022: $23.18 million | Q3 2022: $14.01 million | Q1 2023: $24.63 million | Q2 2023: $19.78 million | Q3 2023: $16.70 million | Q1 2024: $18.87 million | Q2 2024: $19.46 million | Q3 2024: $27.33 million | Q1 2025: $30.91 million | Q2 2025: $32.42 million | Q3 2025: $38.86 million.
- Over the full 10 years of available data (2016 to 2025), Solid Biosciences Inc.'s Research And Development Expense has grown by 597.6%.
- Historical annual values: Fiscal year 2025: $140.33 million | Fiscal year 2024: $96.43 million | Fiscal year 2023: $76.56 million | Fiscal year 2022: $78.42 million | Fiscal year 2021: $58.74 million | Fiscal year 2020: $64.88 million | Fiscal year 2019: $94.74 million | Fiscal year 2018: $57.97 million | Fiscal year 2017: $39.91 million | Fiscal year 2016: $20.12 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: